Full text is available at the source.
Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice
Gut bacteria and bile acids partly help fibroblast growth factor 21 improve fatty liver disease caused by a methionine-choline-deficient diet in mice
AI simplified
Abstract
Patients with non-alcoholic fatty liver disease (NAFLD) exhibited higher serum FGF21 levels and altered fecal microbiota compositions.
- NAFLD is associated with hepatic steatosis, inflammation, fibrosis, and gut microbiota dysbiosis.
- In NAFLD mouse models, FGF21 treatment led to significant reductions in steatohepatitis and collagen deposition.
- FGF21 treatment also restored intestinal structure and modified gut microbiota composition.
- The benefits of FGF21 may be partially attributed to changes in gut microbiota and bile acid metabolism.
- Antibiotic treatment reduced hepatic and intestinal damage in NAFLD mice when combined with FGF21.
- Fecal microbiota transplantation from FGF21-treated mice yielded similar improvements as FGF21 therapy.
AI simplified